Curaxin CBL0137 Exerts Anticancer Activity via Diverse Mechanisms

Ming-Zhu Jin†, Bai-Rong Xia‡, Yu Xu§ and Wei-Lin Jin***

1 Shanghai Jiao Tong University School of Medicine, Shanghai, China, 2 Department of Gynecology, The Affiliated Tumor Hospital, Harbin Medical University, Harbin, China, 3 Key Laboratory for Thin Film and Microfabrication Technology of Ministry of Education, Department of Instrument Science and Engineering, Shanghai Engineering Center for Intelligent Diagnosis and Treatment Instrument, School of Electronic Information and Electronic Engineering, Institute of Nano Biomedicine and Engineering, Shanghai Jiao Tong University, Shanghai, China, 4 National Center for Translational Medicine, Collaborative Innovation Center for System Biology, Shanghai Jiao Tong University, Shanghai, China, 5 Shaanxi Key Laboratory of Brain Disorders and Institute of Basic and Translational Medicine, Xi’an Medical University, Xi’an, China

Chemotherapy with or without radiation remains the first choice for most cancers. However, intolerant side effects and conventional drug resistance restrict actual clinical efficacy. Curaxin CBL0137 is designed to regulate p53 and nuclear factor-κB (NF-κB) simultaneously and to prevent the resistance caused by a single target. Functionally, CBL0137 exhibits an antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer (SCLC). Mechanistically, CBL0137 is originally identified to act by facilitates chromatin transcription (FACT) complex. Further investigations reveal that several pathways, such as NOTCH1 and heat shock factor 1 (HSF1), are involved in the process. CBL0137 has been reported to target cancer stem cells (CSCs) and enhance chemotherapy/monotherapy efficacy. The translational advance of CBL0137 into clinical practice is expected to provide a promising future for cancer treatment.

Keywords: cancer stem cells, CBL0137, chemotherapy, facilitates chromatin transcription, p53

INTRODUCTION

Cancer harbors several characteristics, including high heterogeneity, diverse gene mutation, or rapid progression; consequently, treating cancer is difficult, and it easily relapses. Remarkable achievements have been observed in treatment approaches, including surgery, radiotherapy, chemotherapy, immunotherapy, and targeted therapy. In particular, targeted therapies, such as HER2 inhibitor lapatinib, EGFR inhibitor erlotinib, BRAF inhibitor dabrafenib, promote treatment (1). However, we have failed to treat cancer. Malignancies, such as glioblastoma, are quite invasive and cannot be entirely removed by surgery. Chemotherapy is hindered by innate and acquired chemoresistance.

Originally, antimalarial agents, including quinacrine, can activate p53 and inhibit nuclear factor-κB (NF-κB) simultaneously (2, 3). These drugs have been used as a reference of curaxins, undergoing some structural changes but maintaining similar functions (2, 4). As a second-generation curaxin, CBL0137 satisfies the requirements for a drug design, that is, full efficacy while inducing the least adverse effects. Further research suggested that CBL0137 exerts an antitumor activity through multiple targets, including facilitates chromatin transcription (FACT), NOTCH1, and heat shock factor 1 (HSF1), in various cancers (Table 1). At present, CBL0137 in patients with hematological malignancies (ClinicalTrials.gov Identifier: NCT02931110) and solid tumors are under phase I clinical trials (ClinicalTrials.gov Identifier: NCT01905228). In this review, we
summarized the design of CBL0137, highlighted its antitumor mechanisms through multiple targets, and proposed its potential for clinical applications, especially as a combination drug.

**CBL0137: A SECOND-GENERATION CURAXIN**

Small molecular inhibitor CBL0137 [1,1′-(9-(2-(isopropylamino)ethyl)-9H-carbazole-3,6-diyl)bis(ethan-1-one) (IUPAC/chemical name)] is a second-generation curaxin. Dermawan et al. (12) found that quinacrine (CBLC-102), a first-generation curaxin, can overcome erlotinib resistance through preconceived mechanisms in non-small cell lung cancer (12). Similar results are also observed in ovarian (13) and breast (14) cancers. Second-generation curaxins, such as CBLC-000, CBLC-100, and CBLC-137 (CBL0137), have more exact targets than first-generation curaxins, such as quinacrine (CBLC-102). In particular, CBL0137 is water soluble because of its chemical structure and better tolerated in mice than other members of curaxins, showing great potential for cancer treatment (2). In addition to the two targets, namely, p53 and NF-κB, CBL0137 can intercalate DNA through FACT without causing any DNA damage or genotoxicity (2, 7, 15), and more targets are under investigation.

**FACT: A CORE TARGET FOR CBL0137**

FACT, a histone chaperone, contains two subunits of the suppressor of Ty 16 (SPT16) and structure-specific recognition protein 1 (SSRP1), which participates in DNA replication, transcription, repair, mitosis, and cell fate reprogramming (16–18). SPT16 remodels the histone structure after transcription, and SSRP1 recognizes nucleosomes with its high-mobility group (HMG)-1 domain (19, 20). SSRP1 is considered more like a target since it’s more amplified in cancers at mRNA and protein levels. FACT is involved in the poor prognosis, malignant transformation, tumorigenesis, and aggressiveness of cancers (9, 16, 21–23). It can recognize the formation of alternative DNA structures and promote the activation of p53 to prevent DNA damage (24); thus FACT is regarded as a sensor for genome instability and mutation, which is one of the ten hallmarks of cancer treatment (24, 25) (Figure 1). It is highly expressed in cancer including glioblastoma (GBM) (6), breast cancer (16), and hepatocellular carcinoma (21), but is poor expressed in normal tissues or well-differentiated cells (26).

CBL0137, chemotherapeutic agents, UV radiation, oxygen-free radicals, and hypoxia stress can affect p53 activation (7, 27, 28). With Western Blot analysis, Gasparian et al. (7) have revealed that CBL0137 activates p53 through posttranslational modifications at serine 392 (Ser392) rather than serine 15 (Ser15), which involves casein kinase 2 (CK2) inhibition (7). Previous studies showed that CK2-induced p53 phosphorylation involves FACT. FACT, SPT16, and SSRP1 subunits, can bind to CK2 after CBL0137 is administered, and the SPT16-SSRP1-CK2 complex phosphorylates p53 at Ser392 and promotes p53 activation (2, 27) (Figure 1). Activated p53 induces apoptosis, promotes DNA repair, and inhibits tumor growth. Extensive evidence has also demonstrated that FACT can promote tumor growth, inhibit apoptosis or cell differentiation and induce cell proliferations through the regulation of multiple genes including TP53, MYC, NF-κB, OCT1, and HSF1 (23) (Figure 1).

**CBL0137 EXERTS ANTITUMOR ACTIVITY BY INCREASING P53 AND DECREASING NF-κB SIMULTANEOUSLY**

p53 is a classic tumor suppressor protein responsible for the prevention of oncogenic mutation accumulation, tumorigenesis and tumor progression (29). p53 mutation or inactivation is quite common in many cancers (30). p53 activities are regulated by diverse post-translational modifications such as Ser39 and Ser392 phosphorylation or lysine 382 acetylation and methylation (7, 31). NF-κB is a critical transcription factor in antiapoptosis and cell proliferation, which is activated in inflammation and cancers (32). CBL0137 is originally designed to activate p53 and inhibit NF-κB simultaneously to achieve an enhanced efficacy with modest toxicity (7).

The *in vitro* and *in vivo* experiments of CBL0137 have confirmed the issue. For example, a research on renal cell carcinoma has suggested that CBL0137 intercalates DNA and traps FACT, thereby leading to NF-κB inhibition. FACT binds to CK2 to form a complex, which further induces Ser392 phosphorylation of p53; otherwise, p53 is degraded by MDM2 (2, 7, 33) (Figure 1). Meanwhile, NF-κB is inhibited by the complex (6). Similar results have been shown in GBM research, temozolomide (TMZ)-resistant A1207, TMZ-responsive U87MG cell lines, and orthotopic model. CBL0137 prolongs the survival of orthotopic A1207 and U87MG models, though it is less effective than TMZ in the latter. Furthermore, 0.6 and 2.0 µM CBL0137 can increase p53 significantly in cell lines. These studies have exhibited the antitumor activity of CBL0137 by targeting p53 and NF-κB, which are the two most common transcription factors in oncogenic and tumor suppressor pathways.

**CBL0137 INHIBITS THE SELF-RENEWAL OF CANCER STEM CELLS/TUMOR-INITIATING CELLS THROUGH NOTCH1 ACTIVATION**

Therapeutic resistance is a complex phenomenon in cancer treatment, though many mechanisms have been proposed. “The bad seed” CSCs can explain the consequence to some degree (34). Conventional therapies that do not target CSCs may encounter cancer recurrence because CSCs can undergo self-renewal and differentiation (35). Dermawan et al. investigated CBL0137 in GBM and focused on cancer stem-like cells by using CD133 as
TABLE 1 | Targets and induced effects of CBL0137 reported in cancer research.

| Indications                  | Targets          | Effects                                                                 | Experiment models                      | References |
|------------------------------|------------------|------------------------------------------------------------------------|----------------------------------------|------------|
| Glioblastoma (2)             | FACT↓, p53↑, NF-κB↓ | Induced apoptosis and inhibited proliferation                           | Cell lines, Orthotopic mouse models    | (6)        |
|                              |                  | Increased survival of TMZ-responsive and -resistant GBM                |                                        |            |
| Renal cell carcinoma         | p53↑, NF-κB↓     | Induced death of tumor cells through FACT with no DNA damage          | Cell lines, PDX mouse models           | (7)        |
| Melanoma                     | p53↑, NF-κB↓, HSF1↓ | Enhanced anti-tumor activity by inhibiting heat shock responses of tumor cells | Cell lines, Orthotopic mouse models    | (8)        |
| Neuroblastoma (2)            | SSRP1↓, SPT16↓, MYCN↓ | Reduced tumor initiation and progression                              | Cell lines, TH-MYCN transgenic mouse models | (9)        |
| Small cell lung cancer       | NOTCH1↑          | Reduced the tumor cell growth Preferentially kills tumor-initiating cells | Cell lines, PDX mouse models           | (11)       |

PDX, patient-derived xenograft.

FIGURE 1 | CBL0137 exhibits its antitumor activity via multiple pathways. (1) CBL0137 can target SPT16 and SSRP1, the two subunits of FACT; (2) CBL0137 can induce p53 activation by phosphorylation and NF-κB inhibition, depending on the formation of SPT16-SSRP1-CK2 complex; (3) CBL0137 can reduce the self-renewal of CSCs through NOTCH1 signaling pathway activation; (4) CBL0137 can decrease HSF1 transcription level; (5) CBL0137 can downregulate MYCN expression.

a marker (5). CBL0137 accumulates in brain tissues in orthotopic mouse models, suggesting that it can penetrate the blood brain barrier; oral intake ad libitum can also achieve its efficacy. CBL0137 prefers to inhibit CD133+ tumor cell growth with the help of FACT, which is higher in CSCs than non-stem tumor cells. CBL0137 treatment decreases the expression of CD133 and the self-renewal of CSCs, increases asymmetric cell division, prevents tumor initiation and prolongs the survival of tumor-bearing animals (5). A similar consequence has been demonstrated in small cell lung cancer (SCLC) and pancreatic cancer (11, 36). Tumor-initiating cells (TICs) represent those with stemness, CBL0137 preferentially reduces CD133high and CD44high cells (TICs) over CD133low and CD44low (non-TICs) and attenuate the self-renewal of TICs (11).
The stemness of CSCs is well-modulated by stem-cell factors including p53, NF-κB, Sox2, Bmi1, c-Myc, and NOTCH1 (35, 37). Therefore, drugs should target CSCs and CSC-related factors. NOTCH signaling pathway plays a role in oncogenesis, angiogenesis and CSC maintenance (38). It exhibits oncogenic and suppressive roles in different cancers (11). NOTCH1, as a member of the NOTCH family, increases apoptosis and inhibits cell proliferation in SCLC (11). CBL0137 treatment in SCLC prevents SP3 binding to the NOTCH1 promoter, decreases achaete-scute homolog-1 (ASCL1) expression, increases the mRNA expression of NOTCH1, and inhibits CSC renewal. The expression levels of ASCL1 and SP3 are higher in TICs than non-TICs, negatively modulating NOTCH1. Therefore, the tendency of CBL0137 killing TICs may be a result of FACT and NOTCH1, though whether CBL0137 targeting NOTCH1 acts through FACT is unclear in this research (11). CBL0137 can activate NOTCH1 and inhibit the self-renewal of CSCs/TICs (5, 11, 36), thereby facilitating the enhanced prevention of therapeutic resistance and tumor progression.

HSF1 IS INVOLVED IN THE ANTIMELANOMA EFFECT OF CBL0137

Regional chemotherapy via isolated limb perfusion (ILP) is recommended for patients with in-transit extremity melanoma in which mild hyperthermia (42°C compared with 37°C) is adopted, thereby improving drug uptake by tumor cells (8). CBL0137 was then tested for potential use as a regional chemotherapeutic agent on B16 melanoma cell line and tumor-bearing mice. CBL0137 treatment by ILP reduces SSRP1 expression, suppresses HSF1/hsp70 transcription, and causes tumor cell death, and its efficacy can be improved by hyperthermia. Conversely, CBL0137 can downregulate HSF1 to inhibit heat shock responses brought by hyperthermia, thereby increasing tumor cell apoptosis. However, treatment of traditional melphalan had no statistically significant differences between 42 and 37°C. Moreover, the linkage of the ILP drug melphalan can be highly toxic and cause death. By contrast, even 0.1 mg of CBL0137 establishes a strong antitumor activity, suggesting its leakage causes minimal side effects (8). These results explain the antitumor mechanism of CBL0137 from the perspective of hyperthermia and HSF1, suggesting that CBL0137 can be considered as a promising candidate for ILP drug to treat melanoma.

MYCN IN NEUROBLASTOMA: A POTENTIAL INDICATOR OF CBL0137 SENSITIVITY

Approximately 20% of patients with neuroblastoma encounter MYCN amplification, which is a predictor of poor prognosis (9, 39). Considering that the expression of FACT and MYCN is closely related and high in precancerous TH-MYCN+/+ neuroblasts, Carter et al. (9) treated TH-MYCN+/+ and TH-MYCN+/− mice with CBL0137, which is regarded as the inhibitor of FACT. CBL0137 can downregulate FACT and MYCN expression and inhibit MYCN-driven tumor initiation and progression in MYCN mice and xenografts. In tumor-bearing zebrafish, CBL0137 elicits an inhibitory effect on neuroblastoma (10). Moreover, high-MYCN-expressing cell lines, such as SH-SYSY and BE(2)C, require a lower IC50 of CBL0137 than those expressing normal or relatively low MYCN, suggesting that MYCN expression may be applied to evaluate CBL0137 sensitivity, though further investigation is needed (9).

COMBINATION APPROACH OF CBL0137: THE WAY TO GO

The initial goal of scientists from Clevel and BioLabs Inc. in designing curaxins is to regulate p53 and NF-κB (2). After the “target multiplier” FACT is introduced, the understanding of curaxins has improved. CBL0137 can reduce CSC populations and their stemness (5, 11, 36), which show its promising clinical prospect combined with standard treatment strategies.

The cisplatin resistance of SCLC is likely caused by CSCs. In this research, the combination of CBL0137 and cisplatin at a 1:1 molar ratio remarkably inhibits SCLC tumor growth in H82 xenograft (11). Drug combination delays tumor growth for 30 days and prolongs tumor-bearing mice survival for more than 10 days (11). FACT plays an important role in DNA repair; thus, researchers believed that these results may be due to FACT and its ability to inhibit DNA repair, though this hypothesis has yet to be further investigated (11). However, this hypothesis is partially confirmed in neuroblastoma. Combined with cisplatin, cyclophosphamide, etoposide, or vincristine, CBL0137 can inhibit DNA repair after a double-strand break occurs without genotoxicity. DNA damage markers remarkably increase after etoposide and CBL0137 are administered. The results showed that the effects of CBL0137 are observed in DNA synthesis inhibitors, such as hydroxyurea, rather than microtubule poisons, such as hydroxyurea (9). Another research has shown that the combination of CBL0137 and TMZ does not significantly affect GBM. Combination therapy surpasses CBL0137 monotherapy but not that of TMZ (6). These results are not satisfactory for GBM, but they provide insights into CBL0137 combined with chemotherapy. Further research should be conducted on this area.

Early studies revealed the crosstalk between NF-κB and epidermal growth factor receptor (EGFR), describing them as “partners in cancer” (31, 40–44). In a GBM research, EGFR inhibitor lapatinib and CBL0137 are combined at a 10:1 molar ratio. Lapatinib seldom inhibits CSC growth, which partially explains why it fails to achieve a satisfactory clinical efficacy in GBM treatment (5). The combination of lapatinib and CBL0137 confirms Shostak and Chariot’s outlook and presents possibilities for CBL0137 to be applied with targeted therapy.

CONCLUSIONS AND FURTHER DIRECTIONS

Various small molecules, including PRIMA-1, COTI-2, ReAcp53, ZMCI, PK7088 (45–51), and CBL0137, target
p53 and have been at preclinical and clinical stages. CBL0137 has a broad antitumor activity in a wide range of cancers, other than targeting p53 (7). CBL0137 can be considered as a candidate for monotherapy and applied to enhance the effectiveness of chemotherapy and targeted therapy, giving it more potential and clinical significance.

However, some concerns still exist. Tumor suppressor protein p53 is important in the oncogenic pathway, and almost 50% of cancers possess mutated or depleted p53; thus, resistance likely exists when one path is blocked. In vitro data have also shown that p53-wild type cells are slightly more susceptible to curaxins, including CBL0137-induced cell death, than p53-null cells (7). Discovering how CBL0137 works on those cancers is quite important; in addition, the effect of CBL0137 on the immune system is unknown, and further data support should be obtained to determine whether CBL0137 can synergize with immunotherapy to provide an enhanced efficacy. Further studies on these areas may lead to an in-depth understanding of the mechanism and application of CBL0137.

AUTHOR CONTRIBUTIONS

M-ZJ and B-RX conceived, wrote the manuscript, and completed the figure/table. YX contributed to the writing. W-LJ conceived, organized, and edited the text.

ACKNOWLEDGMENTS

We apologize to those colleagues whose important work could not be cited due to space constraints. This work was in part supported by the 12th undergraduate training programs for innovation of Shanghai Jiao Tong University School of Medicine (No. 1218201), National Natural Science Foundation of China (No. 81872430), the National Key Research and Development Program of China (No. 2017FYA0205302).

REFERENCES

1. Hughes PE, Caenepeel S, Wu LC. Targeted therapy and checkpoint immunotherapy combinations for the treatment of cancer. Trends Immunol. (2016) 37:462–76. doi: 10.1016/j.it.2016.04.010

2. Di Bussolo V, Minutolo F. Curaxins: a new family of non-genotoxic multitargeted anticancer agents. ChemMedChem (2011) 6:2133–6. doi: 10.1002/cmdc.201100476

3. Maluchenko NV, Chang HW, Kozinova MT, Valieva ME, Gerasimova NS, Kitashov AV, et al. Inhibiting the pro-tumor and transcription factor FACT: Mechanisms. Mol Biol. (2016) 50:599–610. doi: 10.1134/S0202689316040087

4. Gurova KV, Hill JE, Guo C, Prokvolit A, Burkhart CA, Safina A, Haderski G, et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-kappaB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA. (2005) 102:17448–53. doi: 10.1073/pnas.0508881102

5. Dermawan JK, Hitomi M, Silver DJ, Wu Q, Sandlesh P, Sloan AE, et al. Preclinical validation of a single-treatment infusion modality of CBL0137. Cancer Res. (2017) 78:2396–406. doi: 10.1158/0008-5472.CAN-17-1920

6. Barone TA, Burkhart CA, Safina A, Haderski G, Gurova KV, Pink J, Dowlati A, De S, Narla G, et al. Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-kappaB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther. (2014) 13:2203–14. doi: 10.1158/1535-7163.MCT-14-0013

7. Khurana A, Roy D, Kalogerot E, Mondal S, Wen X, He X, et al. Quinacrine promotes autophagic cell death and chemoresistance in ovari an cancer and attenuates tumor growth. Oncotarget (2015) 6:36354–69. doi: 10.18632/oncotarget.5632

8. Preet R, Mohapatra P, Mohanty S, Sahu SK, Choudhuri T, Wyatt MD, et al. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer (2012) 130:1660–70. doi: 10.1002/ijc.26158

9. Nesper E, Safina A, Aljahdali I, Portwood S, Wang ES, Koman I, et al. Role of chromatin damage and chromatin trapping of FACT in mediating the anticancer cytotoxicity of DNA-binding small-molecule drugs. Cancer Res. (2018) 78:1431–43. doi: 10.1158/0008-5472.CAN-17-2690

10. Fleyshman D, Prendergast L, Safina A, Paskiewicz G, Commane M, Morgan K, et al. Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells. Oncotarget (2017) 8:20525–42. doi: 10.18632/oncotarget.15656

11. Belotserkovskaya R, Saunders A, Lis JT, Reinberg D. Transcription through chromatin: understanding a complex FACT. Biochim Biophys Acta (2004) 1677:87–99. doi: 10.1016/j.bbamcr.2003.09.017

12. Dermawan JK, Gurova K, Pink J, Dowlati A, De S, Narla G, et al. Quinacrine overcome resistance to erlotinib by inhibiting FACT, NF-kappaB, and cell-cycle progression in non-small cell lung cancer. Mol Cancer Ther. (2014) 13:2203–14. doi: 10.1158/1535-7163.MCT-14-0013

13. Khurana A, Roy D, Kalogerota E, Mondal S, Wen X, He X, et al. Quinacrine promotes autophagic cell death and chemoresistance in ovarian cancer and attenuates tumor growth. Oncotarget (2015) 6:36354–69. doi: 10.18632/oncotarget.5632

14. Preet R, Mohapatra P, Mohanty S, Sahu SK, Choudhuri T, Wyatt MD, et al. Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity. Int J Cancer (2012) 130:1660–70. doi: 10.1002/ijc.26158

15. Nesher E, Safina A, Aljahdali I, Portwood S, Wang ES, Koman I, et al. Role of chromatin damage and chromatin trapping of FACT in mediating the anticancer cytotoxicity of DNA-binding small-molecule drugs. Cancer Res. (2018) 78:1431–43. doi: 10.1158/0008-5472.CAN-17-2690

16. Fleyshman D, Prendergast L, Safina A, Paskiewicz G, Commane M, Morgan K, et al. Level of FACT defines the transcriptional landscape and aggressive phenotype of breast cancer cells. Oncotarget (2017) 8:20525–42. doi: 10.18632/oncotarget.15656

17. Belotserkovskaya R, Saunders A, Lis JT, Reinberg D. Transcription through chromatin: understanding a complex FACT. Biochim Biophys Acta (2004) 1677:87–99. doi: 10.1016/j.bbamcr.2003.09.017

18. Kolundzic E, Ofenbauer A, Bulut SI, Uyar B, Baytek G, Sommermeier A, et al. FACT sets a barrier for cell fate reprogramming in caenorhabditis elegans and human cells. Dev Cell (2018) 46:611–26.e12. doi: 10.1016/j.devcel.2018.07.006

19. Draetta GF, Depinho RA. Cancer drug discovery faces the FACT. Sci Transl Med. (2013) 5:195ps74. doi: 10.1126/scitranslmed.3002530

20. Bondarenko MT, Maluchenko NV, Valieva ME, Gerasimova NS, Kulaeva OL, Georgiev PG, et al. Structure and function of histone chaperone FACT. Mol Biol. (2015) 49:891–904. doi: 10.1134/S0026893315060023

21. Ding Q, He K, Luo T, Deng Y, Wang H, Liu H, et al. SSRP1 contributes to the malignancy of hepatocellular carcinoma and is negatively regulated by miR-497. Mol Ther. (2016) 24:940–14. doi: 10.1038/mt.2016.9

22. Koman IE, Commane M, Paskiewicz G, Hoonjan B, Pal S, Safina A, et al. Targeting FACT complex suppresses mammary tumorigenesis in Her2/neu transgenic mice. Cancer Prev Res. (2012) 5:1025–35. doi: 10.1158/1940-6207.CAPR-11-0529

23. Garcia H, Miecznikowski JC, Safina A, Commane M, Rajasekhar A, Kilpinen S, et al. Facilitates chromatin transcription complex is an "accelerator" of tumor transformation and potential marker and target of aggressive cancers. Cell Rep. (2013) 4:159–73. doi: 10.1016/j.celrep.2013.06.013
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell (2011) 144:66–74. doi: 10.1016/j.cell.2011.02.013
25. Safina A, Cheney P, Pal M, Brodsky I, Ivanov A, Kirsanov K, et al. FACT is a sensor of DNA torsional stress in eukaryotic cells. Nucleic Acids Res. (2017) 45:1925–45. doi: 10.1093/nar/gkw1366
26. Garcia H, Fleyshman D, Kolesnikova K, Safina A, Commane M, Paszkiewicz G, et al. Expression of FACT in mammalian tissues suggests its role in maintaining of undifferentiated state of cells. Oncotarget (2011) 2:783–96. doi: 10.18632/oncotarget.340
27. Keller DM, Lu H. p53 serine 392 phosphorylation increases after UV through induction of the assembly of the CK2.hSPT16.SSRP1 complex. J Biol Chem. (2002) 277:50206–13. doi: 10.1074/jbc.M209820200
28. Keller DM, Zeng X, Wang Y, Zhang QH, Kapoor M, Shu H, et al. A DNA damage-induced p53 serine 392 kinase complex contains CK2, hSpt16, and SSRP1. Mol Cell (2001) 7:283–92. doi: 10.1016/S1097-2765(01)00176-9
29. Kastenhuber ER, Lowe SW. Putting p53 in context. Nat Rev Cancer (2001) 1:41–51. doi: 10.1038/35069540
30. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455:1061–8. doi: 10.1038/nature07385
31. Shi X, Kachirskaia I, Yamaguchi H, West LE, Wen H, Wang EW, et al. Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 455:1061–8. doi: 10.1038/nature07385
32. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. FEBS J. (2017) 284:3273–90. doi: 10.1111/febs.13924
33. Bykov VJN, Eriksson SE, Bianchi J, Wiman KG. Targeting mutant p53 for efficient cancer therapy. Nat Rev Cancer (2018) 18:89–102. doi: 10.1038/s41465-018-0209-0
34. Colak S, Medema JP. Cancer stem cells–important players in tumor therapy resistance. FEBS J. (2014) 281:4777–91. doi: 10.1111/febs.13023
35. Qiu GZ, Sun W, Jin MZ, Lin J, Lu PG, Jin WL. The bad seed. Oncotarget (2014) 5:11038–53. doi: 10.18632/oncota
gre.2701
36. Shetzer Y, Solomon H, Koifman G, Molchadsky A, Horesh S, Rotter V. The paradigm of mutant p53-expressing cancer stem cells and drug resistance. Carcinogenesis (2014) 35:1196–208. doi: 10.1093/carcin/bgu073
37. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. (2014) 141:140–9. doi: 10.1016/j.pharmthera.2013.09.005
38. Danovi S. Neuroblastoma: as a matter of FACT. Nat Rev Cancer (2016) 16:2. doi: 10.1038/nrc.2015.11
39. Shostak K, Chariot A. EGFR and NF-kappaB: partners in cancer. Trends Mol Med. (2015) 21:385–93. doi: 10.1016/j.molmed.2015.04.001
40. Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, et al. EGFR-induced and PKCepsilon monoubiquitylation-dependent NF-kappaB activation upregulates PKM2 expression and promotes tumorigenesis. Mol Cell (2012) 48:771–84. doi: 10.1016/j.molcel.2012.09.028
41. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA. (2000) 97:8542–7. doi: 10.1073/pnas.97.15.8542
42. Le Page C, Kourmakpayi IH, Lessard L, Mes-Masson AM, Saad F. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate (2005) 65:130–40. doi: 10.1002/pros.20234
43. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med. (2002) 8:282–8. doi: 10.1038/nm0302-282
44. Le Page C, Kourmakpayi IH, Lessard L, Mes-Masson AM, Saad F. EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate (2005) 65:130–40. doi: 10.1002/pros.20234
45. Biswas DK, Cruz AP, Gansberger E, Pardee AB. Epidermal growth factor-induced nuclear factor kappa B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA. (2000) 97:8542–7. doi: 10.1073/pnas.97.15.8542
46. Soragni A, Janzen DM, Johnson LM, Lindgren AG, Thai-Quynh Nguyen A, Tsourin E, et al. A designed inhibitor of p53 aggregation rescues p53 tumor suppression in ovarian carcinomas. Cancer Cell (2016). 29:90–103. doi: 10.1016/j.ccell.2015.12.002
47. Yu X, Vazquez A, Levine AI, Carpio DR. Allele-specific p53 mutant reactivation. Cancer Cell (2012) 21:614–25. doi: 10.1016/j.ccr.2012.03.042
48. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, et al. Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res. (2013). 41:6034–44. doi: 10.1093/nar/gkt305
49. Dufky MJ, Swithott NC, Crown J. Mutant p53 as a target for cancer treatment. Eur J Cancer (2017) 83:258–65. doi: 10.1016/j.ejca.2017.06.023
50. Levine AJ, Targeting therapies for the p53 protein in cancer treatments. Ann Rev Cancer Biol. (2019) 3:1. doi: 10.1146/annurev-cancerbio-030518-055455

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.